Arrowhead Pharmaceuticals Corp (ARWR) Commences Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B

March 27, 2018 7:34 AM
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


FDA Management Comments

Next Articles